je.st
news
Tag: is
Jarden Looks Like It Has Legs To Move Higher But The Valuation Is Concerning
2015-08-12 15:03:44| Appliances - Topix.net
Conglomerate Jarden Corp is certainly an interesting company. I first profiled the company back in September 2013 when the stock was trading for about $30.
G is for Google, R is for restructuring
2015-08-11 02:00:00| Total Telecom industry news
C is for CEO as Larry Page hands reins to Sundar Pichai in a bid to make sense of Google's alphabet soup of operations.
Tags: is
r
google
restructuring
Here's where over 90% of the extra heat from global warming is going
2015-08-04 16:12:00| Climate Ark Climate Change & Global Warming Newsfeed
Business Insider: It's no surprise that climate change is raising summer temperatures in many parts of the globe, but what you might not know is where most of that extra heat is going. Scientists estimate that as much as 90% of it is heading straight into our oceans, and that has major consequences not only for marine wildlife but for the world's economy. The average surface temperature around the world has increased by roughly 1.08 degrees Fahrenheit over the last 40 years, but that number would be a lot larger...
And the richest person in Ohio is ...
2015-08-03 16:52:34| Apparel - Topix.net
Forbes has compiled a list of the richest people in each state. In Ohio, the distinction goes to Leslie Wexner , chairman and CEO of Columbus-based L Brands .
In Interim Results from Phase 3 Study, Mercks Investigational Ebola Vaccine Efficacious; Study is Continuing
2015-07-31 14:10:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. Global Collaboration Enabled Vaccine to Move from First-in-Human Studies to Initial Phase 3 Results Within One Year KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (known as MSD outside the US and Canada) said today that its investigational Ebola vaccine candidate, rVSV-ZEBOV, was found to have 100 percent efficacy in an analysis of interim data from a Phase 3 ring vaccination trial in Guinea. Preliminary conclusions from this study, which is continuing, were published on-line today in The Lancet. Language: English Contact: MerckMedia Contacts:Pam Eisele, 267-305-3558orInvestor Contacts:Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Sites : [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] next »